)
Zealand Pharma (ZEAL) investor relations material
Zealand Pharma Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Metabolic Frontier strategy
Around one year into the 2030 strategy, progress includes late-stage obesity programs with Roche and Boehringer, rare-disease advances, a Cambridge, Massachusetts research site opened in September, and partnerships supporting a goal of 10 new metabolic-health clinical programs.
Glepaglutide was approved in Europe; a Phase III study is intended to support a later FDA submission. CHI NDA submission was planned for later in the quarter, with potential approval next year.
Petrelintide and amylin strategy
ZUPREME-1 and ZUPREME-2 data support a potential profile of double-digit weight loss with placebo-like tolerability to date; management sees ease of starting and staying on treatment as a key future differentiator.
Management views amylins as potential first-choice therapies in a patient journey, with combinations or more burdensome treatments added when greater weight loss is needed.
Amylin’s effect on insulin sensitivity may suit early or recent-onset diabetes and potentially prevention; ZUPREME-2 showed no weight-loss penalty in diabetes like the 30%-50% reduction cited for GLP-1s.
A Phase II study of petrelintide with Roche’s enicepatide, a GLP-1/GIP, was expected to start within weeks; the combination is positioned to pursue higher weight loss and address obesity-related comorbidities.
Further amylin innovation includes combinations and alternative administration routes; these programs are a few years behind petrelintide.
Survodutide
The SYNCHRONIZE-CVOT non-inferiority study showed hazard ratios of 0.84-0.9, which management said supported cardiovascular safety; survodutide is eightfold more active on GLP-1 than glucagon.
Management attributed up to 20% dropouts in earlier studies to a fixed titration protocol; Boehringer changed titration protocols in December 2025, and the LIVERAGE MASH study was expected to read out next year.
SYNCHRONIZE-MASLD showed complete liver-fat normalization in 6 of 10 patients; management also cited muscle loss of 10% versus up to 30% with other modalities.
Boehringer is studying survodutide in F2/F3 MASH and cirrhotic patients; management cited MASH in 35% of people with obesity or overweight and excess liver fat in 75%.
- Petrelintide advances to Phase 3 as nine-month revenue reaches DKK 4.529bn.ZEAL
Q3 2026 - AGM adopted all proposals, re-elected the Board and approved expanded share and warrant authorizations.ZEAL
AGM 2023 - Petrelintide and combination therapies advance toward market, with pivotal data and regulatory milestones ahead.ZEAL
Morgan Stanley 24th Annual Global Healthcare Conference - Advanced obesity pipeline, strong cash, and capital allocation despite lower milestone revenue.ZEAL
Q2 2026 - Petrelintide achieved up to 10.7% weight loss with excellent tolerability in Phase 2.ZEAL
Study result - Pivotal clinical milestones and five launches expected by 2030 in metabolic health.ZEAL
44th Annual J.P. Morgan Healthcare Conference - Five launches by 2030, led by petrelintide and survodutide, drive innovation in metabolic health.ZEAL
CMD 2025 - Roche partnership and strong cash position accelerate obesity pipeline and growth.ZEAL
Q1 2025 - Obesity and rare disease pipelines advanced rapidly, with strong cash growth and pivotal trials ahead.ZEAL
Q4 2024
)
)
)
)
)
)
)
)